| pubmed-article:6366138 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6366138 | lifeskim:mentions | umls-concept:C1332884 | lld:lifeskim |
| pubmed-article:6366138 | lifeskim:mentions | umls-concept:C0205527 | lld:lifeskim |
| pubmed-article:6366138 | lifeskim:mentions | umls-concept:C0025677 | lld:lifeskim |
| pubmed-article:6366138 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:6366138 | lifeskim:mentions | umls-concept:C1441547 | lld:lifeskim |
| pubmed-article:6366138 | lifeskim:mentions | umls-concept:C0301630 | lld:lifeskim |
| pubmed-article:6366138 | lifeskim:mentions | umls-concept:C0040808 | lld:lifeskim |
| pubmed-article:6366138 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:6366138 | pubmed:dateCreated | 1984-4-16 | lld:pubmed |
| pubmed-article:6366138 | pubmed:abstractText | During the period 1976-1981, 3241 children were enrolled on three major studies of acute lymphoblastic leukemia by participating institutions of the Children's Cancer Study Group. Each study included a different method of central nervous system (CNS) prophylaxis: (1) standard therapy with cranial irradiation, 2400 rads, and intrathecal methotrexate at 12 mg/m2 six times during consolidation (CCG-141); (2) a modification of CCG-141 in which the intrathecal methotrexate was initiated during induction (CCG-141A); and (3) a reduced cranial irradiation dose of 1800 rads with intrathecal methotrexate given at the same frequency as a CCG-141A, with or without maintenance intrathecal methotrexate, but with a dosage regimen derived from CNS volume considerations rather than based on body surface area (CCG-160 series). Strategy 3, a change in the intrathecal methotrexate dosage, has resulted in the lowest incidence of CNS leukemia to date (p less than 0.007). The cumulative 3-yr CNS relapse rate has decreased from 8%-10% to 2%-5% in average-risk patients (p less than 0.02; life table estimate) and from 23%-27% to 6% in high-risk patients (p less than 0.0002; life table estimate), despite a reduction in the cranial irradiation dose from 2400 to 1800 rads. Maintenance intrathecal chemotherapy has had a marginal effect among patients randomized to receive this additional therapy (p = 0.06). The overall outcome has been an increase in the continuous complete remission rate (p = 0.04) but not in the estimated 3-yr continuous hematologic remission or survival rates. | lld:pubmed |
| pubmed-article:6366138 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6366138 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6366138 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6366138 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6366138 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6366138 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6366138 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6366138 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6366138 | pubmed:month | May | lld:pubmed |
| pubmed-article:6366138 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:6366138 | pubmed:author | pubmed-author:SiegelSS | lld:pubmed |
| pubmed-article:6366138 | pubmed:author | pubmed-author:LeverMM | lld:pubmed |
| pubmed-article:6366138 | pubmed:author | pubmed-author:MillerD RDR | lld:pubmed |
| pubmed-article:6366138 | pubmed:author | pubmed-author:BleyerW AWA | lld:pubmed |
| pubmed-article:6366138 | pubmed:author | pubmed-author:CocciaP FPF | lld:pubmed |
| pubmed-article:6366138 | pubmed:author | pubmed-author:LeikinS LSL | lld:pubmed |
| pubmed-article:6366138 | pubmed:author | pubmed-author:LittmanP SPS | lld:pubmed |
| pubmed-article:6366138 | pubmed:author | pubmed-author:SatherH NHN | lld:pubmed |
| pubmed-article:6366138 | pubmed:author | pubmed-author:LukensJJ | lld:pubmed |
| pubmed-article:6366138 | pubmed:author | pubmed-author:NiebruggeD... | lld:pubmed |
| pubmed-article:6366138 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6366138 | pubmed:volume | 1 | lld:pubmed |
| pubmed-article:6366138 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6366138 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:6366138 | pubmed:pagination | 317-25 | lld:pubmed |
| pubmed-article:6366138 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:6366138 | pubmed:meshHeading | pubmed-meshheading:6366138-... | lld:pubmed |
| pubmed-article:6366138 | pubmed:meshHeading | pubmed-meshheading:6366138-... | lld:pubmed |
| pubmed-article:6366138 | pubmed:meshHeading | pubmed-meshheading:6366138-... | lld:pubmed |
| pubmed-article:6366138 | pubmed:meshHeading | pubmed-meshheading:6366138-... | lld:pubmed |
| pubmed-article:6366138 | pubmed:meshHeading | pubmed-meshheading:6366138-... | lld:pubmed |
| pubmed-article:6366138 | pubmed:meshHeading | pubmed-meshheading:6366138-... | lld:pubmed |
| pubmed-article:6366138 | pubmed:meshHeading | pubmed-meshheading:6366138-... | lld:pubmed |
| pubmed-article:6366138 | pubmed:meshHeading | pubmed-meshheading:6366138-... | lld:pubmed |
| pubmed-article:6366138 | pubmed:meshHeading | pubmed-meshheading:6366138-... | lld:pubmed |
| pubmed-article:6366138 | pubmed:meshHeading | pubmed-meshheading:6366138-... | lld:pubmed |
| pubmed-article:6366138 | pubmed:meshHeading | pubmed-meshheading:6366138-... | lld:pubmed |
| pubmed-article:6366138 | pubmed:meshHeading | pubmed-meshheading:6366138-... | lld:pubmed |
| pubmed-article:6366138 | pubmed:meshHeading | pubmed-meshheading:6366138-... | lld:pubmed |
| pubmed-article:6366138 | pubmed:meshHeading | pubmed-meshheading:6366138-... | lld:pubmed |
| pubmed-article:6366138 | pubmed:meshHeading | pubmed-meshheading:6366138-... | lld:pubmed |
| pubmed-article:6366138 | pubmed:meshHeading | pubmed-meshheading:6366138-... | lld:pubmed |
| pubmed-article:6366138 | pubmed:meshHeading | pubmed-meshheading:6366138-... | lld:pubmed |
| pubmed-article:6366138 | pubmed:meshHeading | pubmed-meshheading:6366138-... | lld:pubmed |
| pubmed-article:6366138 | pubmed:year | 1983 | lld:pubmed |
| pubmed-article:6366138 | pubmed:articleTitle | Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. | lld:pubmed |
| pubmed-article:6366138 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6366138 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:6366138 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:6366138 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:6366138 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:6366138 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6366138 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6366138 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6366138 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6366138 | lld:pubmed |
